GETI.B

202

+0.65%↑

CAMX

669

+0.22%↑

EKTA.B

47.08

-0.08%↓

VITR

129

+0.31%↑

AMBEA

132.4

+0.38%↑

GETI.B

202

+0.65%↑

CAMX

669

+0.22%↑

EKTA.B

47.08

-0.08%↓

VITR

129

+0.31%↑

AMBEA

132.4

+0.38%↑

GETI.B

202

+0.65%↑

CAMX

669

+0.22%↑

EKTA.B

47.08

-0.08%↓

VITR

129

+0.31%↑

AMBEA

132.4

+0.38%↑

GETI.B

202

+0.65%↑

CAMX

669

+0.22%↑

EKTA.B

47.08

-0.08%↓

VITR

129

+0.31%↑

AMBEA

132.4

+0.38%↑

GETI.B

202

+0.65%↑

CAMX

669

+0.22%↑

EKTA.B

47.08

-0.08%↓

VITR

129

+0.31%↑

AMBEA

132.4

+0.38%↑

Home・Akciju saraksts・BioArctic AB

B
BioArctic AB

Slēgts

284.6 -2.47

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

284.2

Max

285.2

Galvenie mērījumi
By Trading Economics
Ienākumi	-896M 179M
Pārdošana	-897M 392M
P/E Sektora vidējais	23.701 35.69
EPS	1.09
Peļņas marža	45.668
Darbinieki	119
EBITDA	-893M 188M

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	4.5B 25B
Iepriekšējā atvēršanas cena	287.07
Iepriekšējā slēgšanas cena	284.6

BioArctic AB Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 26. sept. 18:25 UTC

Galvenie tirgus virzītāji

Mirion Technologies Stock Rises on Expanded Notes, Shares Offerings

2025. g. 27. sept. 07:00 UTC

Peļņas

This Water Stock Is Dehydrated. What Could Bring It Back. -- Barrons.com

2025. g. 27. sept. 04:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 26. sept. 21:56 UTC

Iegādes, apvienošanās, pārņemšana

Staar Surgical, Insight Enterprises, and More Stocks See Action From Activist Investors -- Barrons.com

2025. g. 26. sept. 20:54 UTC

Peļņas

U.S. TikTok for $14 Billion? Making Sense of the Bargain-Basement Price. -- Barrons.com

2025. g. 26. sept. 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2025. g. 26. sept. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 26. sept. 20:27 UTC

Iegādes, apvienošanās, pārņemšana

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

2025. g. 26. sept. 20:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 26. sept. 19:54 UTC

Tirgus saruna

Canada's Can't-Build Reputation Is Somewhat Earned -- Market Talk

2025. g. 26. sept. 19:53 UTC

Iegādes, apvienošanās, pārņemšana

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

2025. g. 26. sept. 19:40 UTC

Peļņas

The U.S. TikTok Is Apparently Fetching a Bargain-Basement Price. A Few Reasons Why. -- Barrons.com

2025. g. 26. sept. 19:24 UTC

Tirgus saruna

U.S. Natural Gas Futures Mixed As October Expires -- Market Talk

2025. g. 26. sept. 19:17 UTC

Tirgus saruna

Oil Posts Weekly Gains on Russia-Ukraine Tensions -- Market Talk

2025. g. 26. sept. 19:15 UTC

Tirgus saruna

AI Deployment Beginning to Weigh on Job Creation, Former Central Banker Says -- Market Talk

2025. g. 26. sept. 19:03 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 26. sept. 19:03 UTC

Tirgus saruna

Gold Fuels Stellar Performance in Toronto Stock Market -- Market Talk

2025. g. 26. sept. 18:50 UTC

Tirgus saruna

Peļņas

Costco's Executive Membership Gains Seen as Offsetting Slower Renewal Rates -- Market Talk

2025. g. 26. sept. 18:36 UTC

Tirgus saruna

Silver Closes Out Week With Strong Surge -- Market Talk

2025. g. 26. sept. 18:02 UTC

Iegādes, apvienošanās, pārņemšana

ING: Continue Working Towards Completing Transaction, Exit From Russian Market >ING

2025. g. 26. sept. 18:02 UTC

Iegādes, apvienošanās, pārņemšana

ING: Global Development Hasn't Received All Necessary Approvals >ING

2025. g. 26. sept. 18:02 UTC

Iegādes, apvienošanās, pārņemšana

ING: No Realistic Prospect of Completing Sale of ING Bank (Eurasia) to Global Development in 3Q

2025. g. 26. sept. 17:54 UTC

Tirgus saruna

U.S. Oil Rig Count Rises For Fifth Straight Week -- Market Talk

2025. g. 26. sept. 16:56 UTC

Tirgus saruna

Peļņas

Costco Increasingly Challenged to Meet Lofty Expectations -- Market Talk

2025. g. 26. sept. 16:41 UTC

Tirgus saruna

Peļņas

Costco's Valuation Seen as Too High Amid Slow Down -- Market Talk

2025. g. 26. sept. 16:26 UTC

Peļņas

Correction to Sherwin-Williams Extends Losses. What's Ailing the Paint Maker. -- Barrons.com

2025. g. 26. sept. 16:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 26. sept. 16:12 UTC

Tirgus saruna

Nike Stock Seen With Limited Upside -- Market Talk

2025. g. 26. sept. 15:59 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 26. sept. 15:59 UTC

Tirgus saruna

Nike Seen Showing Progress in Turnaround -- Market Talk

Salīdzinājums

Cenas izmaiņa

BioArctic AB Prognoze

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par BioArctic AB

BioArctic AB (publ) develops biological drugs for patients with disorders of the central nervous system in Sweden. The company develops Lecanemab, Lecanemab AHEAD 3-45, and Lecanemab Back-up for the treatment of Alzheimer's disease. In addition, the company develops AD-BT2802 and AD-BT2803 drug projects against Alzheimer's disease that are being combined with blood-brain barrier technology and Brain Transporter to promote uptake of antibodies into the brain. Further, it develops BAN1503, BAN2802, BAN2803, and AD2603 for the treatment of Alzheimer's disease; ND-BT3814, ND3014, andGD-BT6822 for the treatment of neurodegenerative disease; and PD1601, PD-BT2238, and PD1602 for the treatment of Parkinson's disease. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.